Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$6.11M-$6.11MN/M vs Q1 2024 EPS Diluted-$2.15-$2.15N/M vs Q1 2024 Operating Income-$1,280,595N/M Operating Cash Flow-$1,117,422N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 19, 2025 · 49 d after period end